Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Maternal exposure to TNF inhibition does not significantly increase infection risk in newborns, according to findings ...

While the link between TNF inhibitor use during pregnancy/postpartum and serious infection risk was not statistically significant, an increased risk cannot be ruled out.

TNF betting tips. From Jason Logan, Covers Senior Industry Analyst. 1. What happened before? Thursday games present a tight ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto’s thyroiditis BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...

Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based ...

“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...